A phase 2 clinical trial found that adding Avastin (bevacizumab) to Alecensa (alectinib) significantly improved outcomes in advanced anaplastic lymphoma kinase (ALK)-positive lung cancer, which then delayed disease progression and protected the brain without compromising quality of life, according to a study published in Nature .

ALK genes are found in about 3% to 9% of non–small cell lung cancer (NSCLC) cases, the study shared.

These genes drive tumor growth by activating specific signaling pathways that help cancer cells survive and multiply.

Patients with ALK-positive NSCLC often respond well to ALK-targeted therapies known as tyrosine kinase inhibitors (ALK-TKIs).

Over the past decade, researchers of this study shared that newer ALK-TKIs have significantly improved patient outc

See Full Page